VE-303 is under clinical development by Vedanta Biosciences and currently in Phase I for Cirrhosis. According to GlobalData, Phase I drugs for Cirrhosis have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VE-303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VE-303 is under development for the treatment of cirrhosis, hepatic encephalopathy, colitis and Clostridium difficile infections. It is administered through oral route and formulated as a capsule. The drug candidate consists of a defined consortia of live bacteria. It acts by modulating pathways of interaction between the human microbiome and the host immune system to treat inflammatory diseases.
Vedanta Biosciences overview
Vedanta Biosciences is a clinical-stage company which focuses on microbiome, which performs critical functions that preserve health including modulating our immune system and providing colonization resistance against infectious pathogens. Vedanta Biosciences is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of VE-303’s drug-specific PTSR and LoA scores, buy the report here.